The present invention relates to miRNA-214-3p and miRNA-1290-3p as biomarkers for prediction or diagnosis of preeclampsia, specifically, at least one selected from miR-214-3p and miR-1290-3p in a sample of a subject A method for predicting or diagnosing preeclampsia, comprising measuring the concentration of microRNA, a composition for predicting or diagnosing preeclampsia comprising a means for measuring the concentration of miR-214-3p or miR-1290-3p, and It relates to a kit for predicting or diagnosing preeclampsia comprising this composition. The preeclampsia biomarkers provided through the present invention, that is, miRNA-214-3p and miRNA-1290-3p, have very excellent sensitivity and specificity, and can be safely and easily applied because they can be measured in blood or serum. It also has the advantage of being able to increase reliability when used in combination because it has a correlation with the biomarker of Therefore, by using the information providing method, composition or kit of the present invention, it is possible to very effectively predict or diagnose preeclampsia of women, especially Korean women.
展开▼
